Development of innovative drugs with an effect on the central nervous system are the key projects of Pikralida start-up for the years to come. A project named EpiFix involves the development of a drug preventing the development of post-traumatic and post-stroke epilepsy. Another project was named ALS, since its aim is to develop a drug dedicated to patients suffering from amyotrophic lateral sclerosis.
The Company’s portfolio also includes projects relating to innovative formulations.
Major challenges associated posed by ongoing projects are described by the founders of the Company in the article entitled “Pikralida has the team at heart”, published in various media such as:
- Puls Biznesu, in the section Rzecz o Innowacjach (Innovations),
- on bankier.pl website (https://www.bankier.pl/wiadomosc/Pikralida-najwazniejszy-jest-zespol-8194600.html)
- on rzeczo.pl website (https://rzeczo.pl/pikralida-najwazniejszy-jest-zespol/)
Read on!
